#13

My best take on the situation: Sinclair spins off a lot of companies based on research from his lab and certainly benefits from them if they make money, but they’re not run by him and they’re not necessarily connected to each other.

  • Metrobiotech: novel NAD+ precursors
  • Life Biosciences: epigenetic reprogramming
  • Tally: TimeSeq epigenetic age testing (which super unfortunately morphed into a subscription service where they send you tests and their very basic supplement)

Most likely the small molecule that does reprogramming is something totally novel, not a current drug or supplement. It would probably fall under Life Biosciences that is doing the eye regeneration trials with gene therapy.

3 Likes
#14

Mitchell B Lee, CEO of Matt Kaeberlein’s Ora Biomedical had this to say about the paper:

https://twitter.com/mitchellblee33/status/1683557462488776706?s=20

Screen Shot 2023-07-24 at 9.58.10 PM
Screen Shot 2023-07-24 at 9.58.10 PM908×1060 84.3 KB

2 Likes
#15

So, this just isn’t making much sense to me. Sinclair is too smart and accomplished I would think to be publishing junk science or to try and con everyone?

2 Likes
#16

Not junk science, but more incremental than monumental.

1 Like
#17

It is a set of compounds that mimick the effect of the OSKM factors. Since OSKM dont actually reverse or slow aging in any major way in healthy animals without progeria, its use is limited.
(aging measured in the sense of a dramatic lifespan increase)

#18

A single cycle of transient OSKM activation in naturally aged mice is able to partially reverse age‐associated changes in several tissues. Specifically, we could capture reversion of alterations occurring with aging at the level of DNA methylation, transcription, as well as, serum metabolome. These changes were stable for a period of up to four weeks after OSKM cessation.

1 Like
Effect of boosters on rapamycin
#19

Ive clarified my post in that its regarding aging as measured by a noticeable increase in lifespan , so far its only been shown in progeric mice. Symptoms of aging are less reliable.

#20

The title of the article is:

Chemically induced reprogramming to reverse cellular aging

Alex Chen, in the referenced thread above, pointed to another article, published on the same day.

Multi-omics characterization of partial chemical reprogramming reveals evidence of cell rejuvenation

The first article studied human cells, while the second study used mouse cells. Both articles have a common co-author - Vadim N. Gladishev.

Gladishev was also co-author in the gene therapy study that produced " Recovery of vision in mice with glaucoma" Gladishev heads the lab that did the mouse study referenced by Alex Chen. Lead author is Gladishev’s post doc, Wayne Mitchell (BS Physics and Mathematics, PhD Biochemistry, Biophysics and Molecular Biology) The human cell study appears to have been conducted at the Sinclair Lab.

Reprogramming to recover youthful epigenetic information and restore vision - PMC.

The list of authors in the gene therapy study includes names familiar to members here.

Yuancheng Lu,1 Benedikt Brommer,2,3,11 Xiao Tian,1,11 Anitha Krishnan,3,4,11 Margarita Meer,5,6,11 Chen Wang,2,3 Daniel L. Vera,1 Qiurui Zeng,1 Doudou Yu,1 Michael S. Bonkowski,1 Jae-Hyun Yang,1 Songlin Zhou,2,3 Emma M. Hoffmann,3,4 Margarete M. Karg,3,4 Michael B. Schultz,1 Alice E. Kane,1 Noah Davidsohn,7 Ekaterina Korobkina,3,4 Karolina Chwalek,1 Luis A. Rajman,1 [George M. Church](Church GM[Author] - Search Results - PubMed),7 Konrad Hochedlinger,8 Vadim N. Gladyshev,5 [Steve Horvath](Horvath S[Author] - Search Results - PubMed),9 [Morgan E. Levine](Levine ME[Author] - Search Results - PubMed),6 Meredith S. Gregory-Ksander,3,4,* Bruce R. Ksander,3,4,* Zhigang He,2,3,* and David A. Sinclair1,10

The papers seem to be attempts to replicate their success in gene therapy by way of chemicals.

In the video below, Sinclair claims that they have done blindness recovery in monkeys (32 seconds)

They will have their first (human) patient “in the next eighteen months”, who has “blindness from either glaucoma or stroke. in the back of the eye.”

2 Likes
#21

Full disclosure. I have a personal interest in their success.

My brother went blind from a pituitary adenoma (as big as an egg). None of that euphemistic legally blind drivel. My brother is totally, black as a black hole blind. So if the Gladishev/Sinclair labs (mention is alphabetical, not by precedence), succeed, there would be hope for my brother.

So I am praying for their success. Pardon the spiritual/non-scientific line.

3 Likes
#22

I recently watched a you tube where a plastic surgeon claimed he could tell that Sinclair had a brow lift.

3 Likes
#23

He made a huge sale when he sold his company Sirtis, to Glaxo for 720 million dollars. Eventually Glaxo had to write off the company when the product didn’t pan out in studies.

1 Like
#24

There’s a video on Youtube somewhere. Someone commented that he looked young for his age and he responded and credited resveratrol, fisetin cycles, and PRP. I assume he meant microneedling with PRP. And that makes sense. It’s one of the best procedures. I think he also mentioned OneSkin once. I don’t think he specifically said he was using it. But maybe he is.

2 Likes
#25

One Skin is a good product. I also think he is using some Botox.

1 Like
#26

It could be all genetics and no special substance, or some unquantifiable combination of the two.

#27

Almost 20 years ago, he was making the same claims about resveratrol. That was disproven. He’s a BS artist. As soon as I saw the headline “Scientist Finds Treatment That Reverses Aging in a Week,” I knew it was him.

4 Likes
#28

He’s a complete BS artist. Trust me, I’ve followed him for almost 20 years. I got wise to him 3-4 years ago.
One example: in his book, he claims that his father had “reversed” his age, that he was climbing mountains etc. in his late 80s. How? NMN & Metformin - that might help with your health, but it definitely won’t “reverse” aging.

4 Likes
#29

Sinclair is a snake oil salesman. Lost a lot of credibility when he sold a company to Glaxo for over 700MM based on resveratol. Glaxo couldn’t reproduce his so called results. Also, his results with NMN have not been reproducible by reputable labs.

3 Likes
#30

I’m following him for some years. After watching his “one Pill” videos on Youtube, I was absolutely impressed. Why?
instead of discussing this topic the normal way (i.e. follow ups or tests from independent labs) he’s creating youtube videos with no content and he’s using buzzwords like yamanaka and AI.

Next thing I’m waiting for is a music video about “one pill” with nice animations.

As a scientist you should always keep an eye on the public and wrting books or publishing YT videos instead of papers is always a good idea, right?

But hey, he’s looking really young. Is this just happiness or is it a filter? I don’t know! :smiley:

Sorry, but after seeing him on YT I was just laughing out loud.

#31

FIlter + facelift + browlift. Probably some fat transfer and/or biostimulators, too. Facelifts on men are not a joke. It takes a very talented surgeon to pull it off successfully. Kudos to his surgeon. I can see it, but from the comments in this forum, most don’t know the telltale signs.

1 Like
#32

I few posts back, I posted a video where Sinclair claims to have had success with restoring visual function in monkeys, after their success with mice, three years ago.

Found an abstract of the paper.

https://iovs.arvojournals.org/article.aspx?articleid=2785785

Investigative Ophthalmology & Visual Science June 2023, Vol.64, 474. doi:

Lead author is Bruce Ksander (ophthalmologist), co-author in the mouse study. Co-author in the paper is the lead author of the mouse study, Lu Yuancheng, Meredith S. Gregory-Ksander (also an ophthalomologist), Joan Mannick (referenced in another post here), and other scientists from the Schepens Eye Research Institute of Massachusetts Eye and Ear.

The study involved twenty green monkeys (monkeys who do not use petroleum?)

Conclusions : Partial epigenetic reprogramming by AAV2-OSK gene therapy restored parameters of visual pathway function in a NHP model of NAION. These data support the clinical translational potential of this gene therapy for treating human optic nerve diseases.

Next stop, humans.

1 Like